TP53 and glioblastoma: In conclusion, our data suggest that TP53 mutations are a predictive biomarker of response to dual mTORC1/2 inhibitors, rendering it worthwhile to further explore dual mTORC1/2 inhibitors in TP53mut glioblastomas.